- Overview:
- The trial is designed to evaluate the safety of CNP-103 and explore if it may help protect insulin-producing beta cells that support better blood sugar control.
- Staus:
- Enrolling
- Clinical Description:
- The purpose of the CNP-103-CL-201 (CNP-103) Clinical Trial is to evaluate the safety, tolerability, pharmacodynamics, and efficacy of an investigational study therapy, CNP-103, in participants ages 12–35 with recent onset Stage 3 type 1 diabetes (T1D).
- Target Age/Sex:
- 12 - 35 years old, Male & Female, diagnosed with Stage 3 T1D in last 6 months.
- Benefits:
- Participants will receive at no cost: study product, study materials and study-specific tests, procedures, and health checks.
- Study Length:
- About 13 Months
- Link:
- ClinicalTrials.gov
- Sponsor Link:
- https://bit.ly/4vJLNud
